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In Multiple Sclerosis (MS) prevalence studies of community and clinical samples, indicate
that 45–60% of patients are cognitively impaired.These cognitive dysfunctions have been
traditionally described as heterogeneous, but more recent studies suggest that there is a
speciﬁc pattern of MS-related cognitive dysfunctions.With the advent of disease-modifying
medications for MS and emphasis on early intervention and treatment, detection of cog-
nitive impairment at its earliest stage becomes particularly important. In this review the
authors address: the cognitive domains most commonly impaired in MS (memory, atten-
tion, executive functions, speed of information processing, and visual–spatial abilities); the
pathophysiological mechanism implied in MS cognitive dysfunction and correlated brain
MRI features; the importance of neuropsychological assessment of MS patients in differ-
ent stages of the disease and the inﬂuence of its course on cognitive performance; the
most used tests and batteries for neuropsychological assessment; therapeutic strategies
to improve cognitive abilities.
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INTRODUCTION
Multiple Sclerosis (MS) is a chronic demyelinating, inﬂammatory
neurological disease, classically considered themost physically dis-
abling non-traumatic neurological disease in young adults. In the
last years many studies have described cognitive dysfunction is
MS patients that contributes signiﬁcantly to their disability sta-
tus (Peyser et al., 1990; Rao et al., 1991a; Benedict et al., 2006).
Prevalence studies of community and clinical samples, indicate
that 45–60% of MS patients are cognitively impaired. Yet, severe
dementia in accordance with the criteria of the ICD-10 is relatively
uncommon, and is observed in 20–30% of cognitively impaired
MS patients, mainly in the ﬁnal stages of the disease (Rao et al.,
1993). The measurement of these neuropsychological abnormal-
ities in the clinical setting, unlike motor and sensory deﬁcits, can
be difﬁcult; and also this difﬁcult exists because MS-related cog-
nitive dysfunctions were traditionally described as heterogeneous
in nature. However, recent studies suggest a more speciﬁc pattern
of MS-related cognitive dysfunction (Chiaravalloti and DeLuca,
2008).
The factors associatedwith cognitive dysfunction in this disease
have not been fully elucidated yet, but several ﬁndings suggest that
cognitive dysfunction could appear in the earliest stages of the dis-
ease as the ﬁrst symptoms of MS (Schulz et al., 2006). Based on the
recent studies appointing for the importance of MS cognitive dys-
function, the authors review the literature and describe: the cogni-
tive domains most commonly impaired in MS, the nature of this
cognitive MS-related impairments, lesion distribution in MRI or
changes in brain structure and correlated cognitive dysfunctions,
the inﬂuence of the course of the disease on cognitive performance,
the importance of neuropsychological assessment of MS patients,
which batteries and tests in neuropsychological assessment are
actually recommended and the inﬂuence of disease-modifying
therapeutics in cognition.
COGNITIVE DOMAINS IMPAIRED IN MS
The cognitive domains impaired in MS seem to have an inter-
patient variability, but a characteristic pattern may be deﬁned:
memory, information processing efﬁciency, executive functioning,
attention, processing speed, are the most commonly compromised
functions (Rao et al., 1991a).
Impaired memory is one of the most consistently impaired cog-
nitive functions in MS and is seen in 40–65% of patients; besides,
MS-related memory dysfunctions most typically affect long-term
and working memory (Rao et al., 1993). The nature of the MS-
related memory impairments is a topic of debate in the literature,
some studies suggest that memory dysfunctions in MS result pri-
marily from impaired retrieval from long-term memory, whereas
encoding and storage capacity seems to remain intact (Thornton
et al., 2002). Recent research on the nature of memory dysfunc-
tion in MS shows that MS patients have difﬁculty with acquisition
of new knowledge as opposed to retrieval from long-term stor-
age (Chiaravalloti and DeLuca, 2008). Initially, based on the work
of Rao and colleagues it was thought that memory difﬁculty was
due to impaired retrieval, but more recent explanations are based
in inadequate acquisition secondary to information processing
insufﬁciency.
Impaired speed of information processing has been identiﬁed as
a key deﬁcit inMS (Bergendal et al., 2007) and is seen in 20–30%of
patients. Information processing efﬁciency refers to the ability to
maintain and manipulate information in the brain for short time
period and to the speed with which one can process that infor-
mation. Processing speed deﬁcits are observed on even the most
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basic tasks in MS patients and are related with decreased neuronal
conduction speed secondary to demyelinating. This slowed infor-
mation processing may impact an individual’s ability to complete
tasks and to cope in demanding work (Archibald and Fisk, 2000).
Executive functions concern to the cognitive abilities necessary
to behavior directed to objectives and to the adaptation to environ-
ment demands and changes; examples are planning, organization,
reasoning, and abstract conceptualization. Deﬁcits in executive
functions in MS patients (detected in 19% of the patients) occur
less frequently thanmemory or processing speed disability. ButMS
patients have speciﬁc impairment deﬁcits in some executive func-
tions, especially in generating strategies, divergent thinking, prob-
lem solving and estimation (Rao et al., 1991a). So, abstract reason-
ing, verbal ﬂuency, planning, or problem solving capabilities, have
been shown to be frequently reduced in MS patients.
Attention is also a complex cognitive function and comprehends
different aspects like alertness, vigilance, selective or focused and
divided attention. Up to 25% of MS patients have deﬁcits in atten-
tion, especially in complex functions like selective and divided
attention (Nebel et al., 2007).
NEUROPSYCHOLOGICAL ASSESSMENT
The assessment of cognitive functions is undoubtedly important
in MS patients, however it is not wise to rely on the routine neu-
rological consultation. Cognitive symptoms are usually hidden
by more visible deﬁcits (e.g., motor, sensory, cerebellar), may be
masqueraded by emotional complains, as depression, by fatigue or
pain andmost times are not thoroughly recognized by the patients.
Besides, the predominant subcortical nature of cognitive impair-
ment in MS is not suited to the current tests employed more often
by neurologists in the clinical setting, as, for instance the Mini-
Mental State Examination (MMSE) in dementia syndromes; yet,
MMSE might be useful for quick screening of cognitive impair-
ment before the application of more speciﬁc batteries in selected
cases (Rao, 1986).
Since the pioneering reports of Rao and co-workers in the
nineties (Rao andCognitive Function StudyGroup of theNational
Multiple Sclerosis Society, 1990; Rao et al., 1991a,b), the charac-
teristics of cognitive dysfunction in MS and the appropriate tests
for its detection have been extensively addressed in the literature
(Benedict et al., 2002; Montalban and Rio, 2006; Benedict and
Zivadinov, 2007; Strober et al., 2009; Comi, 2010; Ferreira, 2010;
Kinsinger et al., 2010; Lyros et al., 2010;Messinis et al., 2010;Arnett
and Strober, 2011; Langdon, 2011). In general, cognition in MS
may be assessed by two separate, yet complementary, modes: the
self-reported evaluation of MS patients and relatives and the neu-
rocognitive batteries adapted to the disease. As elsewhere stated,
the self-reported cognitive impairment is prone to depend more
on the emotional status, depressive and fatigue complains rather
than on real cognitive test performance; on the contrary, the eval-
uation of relatives and caregivers is usual more reliable (Kinsinger
et al., 2010). Even so, the self-perceived cognitive dysfunction is
important for the patients to be aware of its impact in daily life
activities and to overcome items related with the disease itself, as
treatment adherence or scheduled appointments.
The neuropsychological tests and batteries indicated for mea-
suring the cognitive domains which are compromised in MS
patients require expertise and are still matter of debate in the liter-
ature. Ideally, the neuropsychological tests and batteries should
be sensitive, reproducible, reliable easy to administer and last
few time, taking into account the patient’s comfort, the human
resources of MS clinics and the implied costs. These batteries need
to have good normative data, corrected for age, and education
level. In parallel, tests to evaluate depression and fatigue must be
performed, since those symptoms have a recognized impact in
cognitive abilities (Kinsinger et al., 2010). In a recent systematic
review, the use of 23 batteries and 74 neuropsychological tests was
identiﬁed in the literature, which means a lack of homogeneity in
this issue despite the recognized consensus on the characteristics
of cognitive impairment in MS patients (Ferreira, 2010).
Two cognitive batteries are particularly relevant and validated
in MS, being widely used in clinical practice and also for research
purposes: the Brief Repeatable Battery of Neuropsychological tests
(BRBN; Rao and Cognitive Function Study Group of the National
Multiple Sclerosis Society, 1990) and the Minimal Assessment of
Cognitive Function in MS (MACFIMS; Benedict et al., 2002). The
BRNB is composed by tests that were found to be most sensitive
to the cognitive impairment in MS, after a previous application of
a comprehensive neuropsychological battery (Rao and Cognitive
Function Study Group of the National Multiple Sclerosis Soci-
ety, 1990), as follows: the selective reminding test (SRT), the 7/24
(later substituted by the 10/36) spatial recall test, the controlled
oral word association test (COWAT), and the paced auditory
serial addition test (PASAT). These measures achieved 71% sen-
sitivity and 94% speciﬁcity when compared with the more com-
prehensive neuropsychological battery. Later the authors revised
the battery to include the symbol digit modality test (SDMT)
that evaluates the speed of information processing. In 2002 a
group of experts on neuropsychological functioning in MS from
different countries created by consensus the MACFIMS battery
(Benedict et al., 2002), choosing tests according to their sensitiv-
ity to the disease, reliability, validity, ease of administration and
the presence of alternate types to make the repeat testing feasi-
ble. This battery is composed of seven neuropsychological tests,
covering ﬁve cognitive domains commonly impaired in MS (pro-
cessing speed/working memory, learning and memory, executive
function, visual–spatial processing, and word retrieval) and takes
around 90min to administer. Speciﬁcally, the battery includes the
PASAT and the SDMT for Processing speed/Working memory,
the California Verbal Learning Test-II and the Brief Visuospa-
tial Memory Test – Revised (BVMTR) for Learning and Memory,
the D-KEFS Sorting Test for Executive Functions, the Judgment
of Line Orientation Test for Visual perception/Spatial process-
ing and the COWAT for Language. Besides, additional tests are
recommended in the MACFIMS, such as measures of premor-
bid ability with word recognition tests which are not affected
in MS, visual screening to evaluate the impact of visual symp-
toms on neuropsychological tests based in visual tasks, screening
of motor problems with the 9-Hole Peg Test, screening of oral
motor speed deﬁcits since some tests require rapid answers, and
also fatigue evaluation with the Fatigue Impact Scale (Benedict
et al., 2002).
Brieﬂy, the BRNB and the MACFIMS batteries are quite similar,
only differing in the tests that assess the speciﬁc auditory–verbal
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and visual–spatial memory: whereas the former employs the SRT
and the 10/36 Spatial Recall Test (10/36), the latter uses theCalifor-
nia Verbal Learning Test, Second Edition (CVLT2) and BVMTR.
Nevertheless,bothbatterieswere found tohave identical sensitivity
in a comparative study (Strober et al., 2009), being the SDMT the
most sensitive measure.
Despite the consortium recommendation for the use of MAC-
FIMS (Benedict et al., 2002) in MS, the BRNB (Rao and Cognitive
Function Study Group of the National Multiple Sclerosis Society,
1990) remains, up to now, the most widely used neuropsycholog-
ical battery for assessing cognitive functions in the disease. The
longer experience in applying the BRNB, and the fact that it has
been traduced and validated in some populations might explain
its traditional use. The BRBN is also routinely since several years in
our MS Clinic, where the neuropsychologists have acquired exper-
tise in the performance of the tests and interpretation of the results
(Rio et al., 2004; Barbosa et al., 2011a). Nonetheless, it must be
highlighted that the MACFIMS presents some advantages regard-
ing the BRBN, as it is easy to administer and the included measures
demonstrate good psychometrics. Besides the MACFIMS battery
is suited to repeated assessments which, ideally, should be peri-
odically conducted in the follow-up of the disease progression
(Benedict et al., 2002).
NATURE OF COGNITIVE MS-RELATED IMPAIRMENTS
The mechanism underlying cognitive impairment in MS has not
been fully elucidated. Cognitive decline in MS patients has been
correlated with both macro- and microscopic changes in brain
anatomy; and this has been demonstrated by using structural
and functional brain imaging. Recent studies have shown that
both gray and white-matter lesions contribute to mental dys-
function in MS (Morgen et al., 2006; Dineen et al., 2009). Ini-
tially, some studies correlate white-matter lesions localizations
with speciﬁc cognitive impairments (Rao et al., 1989). For exam-
ple a white mater lesion in frontal lobe lesions has been shown
to affect performance in tests of frontal lobe function (Rovaris
et al., 1998). Also it was demonstrated that there is a signiﬁ-
cant association between executive deﬁcits and damage in the
prefrontal cortex (Foong et al., 1997) and frontal and parietal
lesion burden has been shown to correlate with performance on
tests of complex attention and verbal working memory (Sper-
ling et al., 2001). This relationship between speciﬁc white lesion
location and cognitive performance was also demonstrated in
early stage of MS. For example Ranjeva (2006) studied patients
with clinically isolated syndromes and cognition impairment and
conclude that poorer performance in processing speed and work-
ing memory was associated with abnormalities in the splenium
of the corpus callosum and in the right superior longitudinal
fasciculus.
More recent investigation, discussed the contribution of ultra-
structural tissue injury in normal-appearing white-matter and the
correlation between cognitive dysfunction and gray–white-matter
lesions (Kidd et al., 1999; Geurts et al., 2005; Sanﬁlipo et al., 2006).
The correlation between multifocal white-matter and gray-matter
lesions in cognitive dysfunction pathology has geared the discon-
nection theory. This model is based in the predilective topology
of MS-associated lesions, predominantly involving subcortical
periventricular ﬁber systems, which hinders distal ﬂow of corti-
cal cholinergic pathways. Disconnection occurs between cortical
and subcortical regions interactions (Amato et al., 2004; Morgen
et al., 2006). Cortical involvement related to MS is heterogeneous
since it may arise from local demyelinating lesions, meningeal
inﬂammation, neuronal injury, and Wallerian or transsynaptic
degeneration (Nelson et al., 2011). As well, selective decrease of the
cortical volume was found in patients with relapsing–remitting
(RR) MS and mild cognitive deﬁcits; this was associated with
poorer performance on tests of verbal and spatial memory, atten-
tion and concentration, and verbal ﬂuency (Piras et al., 2003). MS
patients with cognitive deﬁcits showed more cortical lesions and
more severe cortical atrophy than patients who were cognitively
preserved (Calabrese et al., 2009). But this cortical involvement
is better understand by subcortico-cortical involvement with the
multiple disconnection syndrome, in which a more than one cog-
nitive domain can be interrupted in its afferent or efferent loop,
producing a variety of neuropsychological defects (Calabrese and
Penner, 2007). Also in recent study, Dineen et al. (2009) con-
ﬁrm that MS-related cognitive dysfunction results from a series of
domain-speciﬁc disconnectionphenomena.As such,disruptionof
critical white-matter tracts will lead to reduced functional connec-
tivity between cortico-cortical and cortico-subcortical cognitive
processing regions, resulting in impairment to speciﬁc cognitive
domains.
MAGNETIC RESONANCE IMAGING AND COGNITIVE
IMPAIRMENT
Conventional and non-conventional magnetic resonance imaging
(MRI) measures have been correlated with cognitive impairment
in MS. Initially Rao et al., 1991a) examined by a conventional way
a number of MRI variables including total lesion area, ventricular-
brain ratio and size of the corpus callosum. In the past few
years, a large effort has been devoted to the development of MRI
techniques with the ability to characterize in vivo the different sub-
strates of gray-matter and white-matter damage to improve the
understanding of its clinical consequences in MS patients (Rinaldi
et al., 2010).
Measures of brain atrophy are particularly sensitive in eluci-
dating the relation between brain integrity and cognitive status
(Calabrese et al., 2009). Longitudinal imaging studies have shown
a strong correlationbetween changes in cognitive functioning, sug-
gesting that a progression of brain atrophy early in the disease can
predict cognitive impairment 5 years later (Summers et al., 2008).
Recent MRI studies, which assessed the extent of brain tissue loss
on a regional basis, have suggested that cortical volume loss is
more closely associated with cognition than whole-brain atrophy.
More recently, the application of double inversion recovery (DIR)
sequences has convincingly demonstrated that cortical lesions are
a frequent ﬁnding in patients with MS, even at the earliest clinical
stages (Calabrese et al., 2009).
Quantitative imaging techniques, such as diffusion tensor
imaging (DTI) are a powerful non-invasive technique for explor-
ing cerebral ultrastructure. Fractional anisotropy (FA), a para-
meter derived from DTI data provides a quantiﬁcation of ultra-
structural ﬁber organization (Basser and Pierpaoli, 1996). DTI
examination of MS patients has revealed reduced FA in plaques,
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adjacent to plaques and to varying degrees in normal-appearing
white-matter (Kealey et al., 2005). Measures derived from mag-
netization transfer ratio have also consistently been shown to
be associated with cognition, as documented with many types
of brain tissue, including cortical and subcortical regions and
normal-appearing white-matter tissue on conventional imag-
ing. Magnetic resonance spectroscopy, which provides a mea-
sure of metabolic changes in the cerebral cortex and white-
matter, is also a sensitive indicator of cognitive functioning in
MS, particularly in normal-appearing white-matter (Staffen et al.,
2002).
Functional MRI (fMRI) has brought new insight into a bet-
ter understanding of cognitive impairment at the very early stage
of MS (Audoin et al., 2006). Brain connectivity assessed by fMRI
have provided new data about the real inﬂuence of diffuse white-
matter damageon connectivity efﬁciency. fMRIhas evidencedhow
the brain accommodates to diffuse white-matter injury during
controlled information processing task. Brain activation observed
by fMRI permits the understanding of cortical reorganization
processes and the disturbance in brain connectivity (Ranjeva et al.,
2005).
COURSE OF THE DISEASE AND COGNITIVE PERFORMANCE
Some studies suggest an inﬂuence of the course of the disease
on cognitive performance. Although some studies indicate that
cognitive dysfunction is more frequent and severe in the progres-
sive forms of MS (Beatty et al., 1989), cognitive impairment can
be present since the early clinical stages of the disease. Moreover,
another study pointed out that different courses of the disease
are associated with different cognitive proﬁles (Huijbregts et al.,
2004). It was shown that chronic progressive MS patients were
more likely than RRMS patients to suffer from attention deﬁcits,
in particular reduced speed of information processing, executive
dysfunctions, verbal intelligence and abstraction deﬁcits. Also a
recent study (Schulz et al., 2006) investigated patterns of cognitive
decline in MS patients in the early stage of the disease and neu-
ropsychological assessment revealed cognitive impairments of MS
patients in the early stage of their disease. Between 10 and 38% of
the MS patients displayed signiﬁcantly lengthened reaction times
and deﬁcient attention. Reduced speed of information processing
may be a fundamental neuropsychological deﬁcit in the earliest
stages of the disease.
Throughout the course of the disease, some other clinical
problems can intensify or simulate cognitive deﬁcits. Speciﬁcally,
depression or fatigue must be discriminated from cognitive dys-
functions. Up to 90% of MS patients suffer from fatigue, a subjec-
tive lack of energy, which can reduce cognitive performance; on
the other hand, cognitive deﬁcits can produce exhaustion (Engel
et al., 2007). Fatigue might affect performance over time in tasks
that require sustained mental effort, specially in cognitive tasks of
working memory and visual vigilance (Krupp and Elkins, 2000).
Psychiatric symptoms of MS, like anxiety and depression, which
can appear in up to 50% of the patients, have a signiﬁcant effect
on subjective perceived performance (Landro et al., 2004). Depres-
sion affectsmany aspects of cognitive functioning inMS, including
working memory, processing speed, learning and memory func-
tions, abstract reasoning, and executive functioning (Chiaravalloti
and DeLuca, 2008). In addition, an anamnesis of medication is
necessary, because many therapeutic agents like antidepressants,
anticonvulsants, antispastics, glucocorticosteroids, or neuroleptics
can produce cognitive impairment, especially in attention (Engel
et al., 2007).
TREATMENT OF COGNITIVE DYSFUNCTION
The treatment of cognitive symptoms in MS patients begins with
the patient education about the possibility of their occurrence
and with an open relation with the MS team, to favor the earliest
recognition as possible. As soon as the patients become aware of
cognitive impairment the better, because they may be quickly sub-
mitted to neuropsychological assessment and request someone’s
help, if needed, for daily life activities.
At ﬁrst, some general advices may be provided, as simple tools
to improve cognitive abilities: strategies to organize the informa-
tion (use of scheduled agendas and elaboration of lists of tasks),
offer more time to perform usual tasks and process information,
taking into account that the impairment of informationprocessing
speed is characteristic of cognitive dysfunction inMS.As elsewhere
described, paring down information to the essentials and avoid-
ing unnecessary or unrelated details are advantageous (Langdon,
2010).
Most important, the treatment of MS with disease-modifying
drugs (DMD) is naturally expected to bring some beneﬁts in
cognitive functioning, in parallel with the improvement in clin-
ical outcomes (reduction of the annualized relapse rate, disability
progression) and MRI parameters (new T2 lesions, gadolinium-
enhancing lesions), in as much as DMD act by controlling inﬂam-
mation, reduce the accumulation of lesions and somewhat might
have a neuroprotective role (Mendes and Sá, 2011; Sá et al.,
2011). However, as repeatedly emphasized in the literature (for
review see Comi, 2010), the results of DMD in cognition must
be cautiously interpreted because they generally have consider-
able drawback. In effect, the largest clinical trials (pivotal phase
III studies, extension phases) of DMD do not include cognitive
parameters in the primary outcomes and when those assessments
were done the psychometric measures vary with different studies,
use different samples sizes, MS populations, and statistic analy-
ses, which altogether prevents their comparability (Montalban
and Rio, 2006; Comi, 2010; Lyros et al., 2010). Focusing only
on randomized double-blind, placebo-controlled studies, some
positive results in cognition were seen with interferon beta-1a
in RR forms (Fischer et al., 2000), with interferon beta-1b in
RR (Pliskin et al., 1996), secondary progressive forms (European
Study Group, 1998), and clinically isolated syndromes (Kappos
et al., 2009); on the contrary, glatiramer acetate showed no cog-
nitive beneﬁt in RR patients (Weinstein et al., 1999). In addition,
clinical trials speciﬁcally designed to evaluate cognition are scarce.
In the IMPACT trial, designed to assess whether weekly intra-
muscular IFN b-1a reduces disability progression in SPMS, the
MS functional composite (MSFC) that includes PASAT was used
as primary endpoint, a modest effect 2 years after the baseline
evaluation was detected (Cohen et al., 2002). In the CogniMS
study, performed to evaluate cognition, fatigue, depression, and
quality of life in patients with early MS treated with interferon
beta-1b, cognitive scores improved over time, which seemed to
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be due to practice effects (Langdon et al., 2010); however data
have not yet been published so far. With respect to natalizumab,
an improvement was noticed in the PASAT tests performed dur-
ing the MSFC evaluations, and in the mental component of
SF-36 in both pivotal trials (Polman et al., 2006; Rudick et al.,
2006).
Another pharmacological attempt to ameliorate cognitive dys-
function in MS has been the use of licensed drugs for dementia
diseases, despite the existence of substantive differences between
the nature of cognitive deﬁcits in both situations and their respec-
tive underlying pathogenetic processes in the CNS. Even so, some
authors have tried acetylcholinesterase inhibitors, as donepezil,
rivastigmine, and galantamine, as well as memantine, an antago-
nist of NMDA receptors (Doraiswamy and Rao, 2004). Donepezil
(10mg/day) showed an improvement in learning and memory in
a randomized placebo-controlled trial enrolling 69 MS patients
(Krupp et al., 2004), further showing clinical beneﬁt to patients
and physicians (Christodoulou et al., 2006); however negative
results were recently reported by other groups which found that
donepezil 10mg daily for 24 weeks is not superior to placebo
in improving MS-related cognitive dysfunction, in randomized
control trials (Krupp et al., 2011; O’Carroll et al., 2012). Rivastig-
mine has also been tested in MS patients with neurocognitive
dysfunction, where no beneﬁt in a general score memory in com-
parison to placebo (Shaygannejad et al., 2008) or a trend to an
improvement in cognitive processing speed by enhancing com-
pensatory brain activation (Huolman et al., 2011) have been found
so far; positive effects were detected in imaging studies, since MS
patients treated with rivastigmine displayed increased brain activ-
ity during cognitive tasks in fMRI studies (Parry et al., 2003).
The effect of memantine given 10mg twice a day in MS patients
with cognitive impairment has been evaluated in a randomized
placebo-controlled trial, which failed to show any positive result
(Lovera et al., 2010). Based on the assumption that these drugs
might have positive effects in cognitive impairment of MS, they are
sometimes used off label in the clinical setting, especially in cases
with overt dementia symptoms, mimicking primary degenerative
dementias. However, up to now there is insufﬁcient evidence of
the efﬁciency of these drugs in MS and their role in the cognitive
decline of MS patients is still controversial (Christodoulou et al.,
2008), awaiting speciﬁcally designed trials allowing longitudinal
assessments. As stated in a recent Cochrane review of this sub-
ject, until the results of ongoing studies are available, there is no
convincing evidence to support pharmacologic intervention as an
effective treatment for memory disorder in MS patients (He et al.,
2011).
Finally, the importance of cognitive rehabilitation must be
stressed, which is a ﬁeld that needs to be better explored, bearing
in mind that it still lacks a consistent evidence base. The concept of
submitting cognitively impaired MS patients to techniques of cog-
nitive rehabilitation was based in the knowledge obtained in other
CNS pathologies, as stroke. As cognitive dysfunction was more
and more studied in MS, the need for the development of cog-
nitive rehabilitation increased, originating an extensive literature
that is rather difﬁcult to appreciate becausemethods and technolo-
gies vary with the study. The rationale for cognitive rehabilitation
relies upon the stimulation of the natural restorative phenom-
ena taking place in CNS in response to some kind of injury,
as inﬂammation and demyelination, which is commonly called
neuroplasticity. Recent fMRI studies showed that brain activity
in the cerebellum of cognitively impaired MS patients increased
with a cognitive rehabilitation program (Sastre-Garriga et al.,
2011).
Brieﬂy, two types of strategies have been pointed out: com-
pensatory and restorative. Compensatory approaches are easier
for patients and caregivers to carry out and include all measures
that favor learning and memory, as above-mentioned organizers
of information and memory aids in general. Restorative strategies
are based in the plastic properties of the nervous system (e.g.,
cortical reorganization), and are more ambitious because they
identify speciﬁc impaired cognitive functions in each patient and
then introduce techniques that aim to increase the performance
in those tasks, ideally to provide a successful recover or reme-
diation (Messinis et al., 2010). As part of restorative strategies,
several computerized programs have been developed and applied
to MS patients with cognitive impairment targeting different cog-
nitive domains. In general, most studies suggest that memory is
the cognitive domain with major improvement, namely spatial
memory (Barbosa et al., 2011b) and episodic memory (Brissart
et al., 2011). The studies of memory training suggest that speciﬁc
patient-individualized computerized schemas are more effective
(Langdon, 2011); conversely, programs focusing working mem-
ory, attention and executive functions are less developed so far.
With respect to executive skills, the direct training by a therapist
seems to be more successful (Langdon, 2010). The effects of neu-
ropsychological rehabilitation in MS has been recently addressed
in an extensive systematic review that only included randomized
controlled trials and quasi-randomized trials in comparison with
other interventions or any kind of intervention; the authors stress
methodological limitations and heterogeneity in the interventions
included in the review, the low level evidence for the positive effects
of neuropsychological rehabilitation in MS, and give recommen-
dations to improve the quality of futures studies about this issue
(Rosti-Otajärvi and Hämäläinen, 2011).
CONCLUSION
Neuropsychological assessment is not required to diagnose MS
(Polman et al., 2005) and cognitive deﬁcits may not be evident
during a follow-up consultation in clinical practice. But with the
advent of DMD for MS and emphasis on early intervention and
treatment, detection of cognitive impairment at its earliest stage
becomes particularly important, in as much as the patients may
also beneﬁt of symptomatic and rehabilitation interventions.
Thus, with this revision the authors are able to conclude that: it
is important to include cognitive evaluation of MS patients in clin-
ical routine, since these cognitive deﬁcits may be present in early
phases of disease; the standardization of cognitive proﬁle eval-
uation seems to be mandatory in MS patients; MRI is crucial in
the understanding and follow-up of MS cognitive impairment; the
therapeutic strategies to improve cognitive abilities need to be bet-
ter evaluated with appropriately designed randomized controlled
trials.
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